Literature DB >> 21533634

Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results.

Oguz Akin1, David H Gultekin, Hebert Alberto Vargas, Junting Zheng, Chaya Moskowitz, Xin Pei, Dahlia Sperling, Lawrence H Schwartz, Hedvig Hricak, Michael J Zelefsky.   

Abstract

OBJECTIVES: To assess the incremental value of diffusion-weighted (DW-MRI) and dynamic contrast-enhanced MRI (DCE-MRI) to T2-weighted MRI (T2WI) in detecting locally recurrent prostate cancer after radiotherapy.
METHODS: Twenty-four patients (median age, 70 years) with a history of radiotherapy-treated prostate cancer underwent multi-parametric MRI (MP-MRI) and transrectal prostate biopsy. Two readers independently scored the likelihood of cancer on a 1-5 scale, using T2WI alone and then adding DW-MRI and DCE-MRI. Areas under receiver operating characteristic curves (AUCs) were estimated at the patient and prostate-side levels. The apparent diffusion coefficient (ADC) from DW-MRI and the K(trans), k(ep), v(e), AUGC90 and AUGC180 from DCE-MRI were recorded.
RESULTS: Biopsy was positive in 16/24 (67%) and negative in 8/24 (33%) patients. AUCs for readers 1 and 2 increased from 0.64 and 0.53 to 0.95 and 0.86 with MP-MRI, at the patient level, and from 0.73 and 0.66 to 0.90 and 0.79 with MP-MRI, at the prostate-side level (p values < 0.05). Biopsy-positive and biopsy-negative prostate sides differed significantly in median ADC [1.44 vs. 1.68 (×10(-3) mm(2)/s)], median K(trans) [1.07 vs. 0.34 (1/min)], and k(ep) [2.06 vs 1.0 (1/min)] (p values < 0.05).
CONCLUSIONS: MP-MRI was significantly more accurate than T2WI alone in detecting locally recurrent prostate cancer after radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533634      PMCID: PMC3730825          DOI: 10.1007/s00330-011-2130-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

1.  Nonparametric analysis of clustered ROC curve data.

Authors:  N A Obuchowski
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

2.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

3.  Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.

Authors:  J Crook; S Malone; G Perry; Y Bahadur; S Robertson; M Abdolell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-09-01       Impact factor: 7.038

Review 4.  Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

Authors:  J D Cox; M J Gallagher; E H Hammond; R S Kaplan; P F Schellhammer
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

5.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Authors:  Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

Review 6.  Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients.

Authors:  J M Crook; G A Perry; S Robertson; B A Esche
Journal:  Urology       Date:  1995-04       Impact factor: 2.649

7.  Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings.

Authors:  Olivier Rouvière; Olivier Valette; Stéphanie Grivolat; Catherine Colin-Pangaud; Raymonde Bouvier; Jean Yves Chapelon; Albert Gelet; Denis Lyonnet
Journal:  Urology       Date:  2004-05       Impact factor: 2.649

8.  Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

Authors:  Deborah A Kuban; Howard D Thames; Larry B Levy; Eric M Horwitz; Patrick A Kupelian; Alvaro A Martinez; Jeff M Michalski; Thomas M Pisansky; Howard M Sandler; William U Shipley; Michael J Zelefsky; Anthony L Zietman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-15       Impact factor: 7.038

Review 9.  Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.

Authors:  L Boccon-Gibod; W B Djavan; P Hammerer; W Hoeltl; M W Kattan; T Prayer-Galetti; P Teillac; U W Tunn
Journal:  Int J Clin Pract       Date:  2004-04       Impact factor: 2.503

Review 10.  Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy.

Authors:  Andrew J Stephenson; Peter T Scardino; Fernando J Bianco; James A Eastham
Journal:  Curr Treat Options Oncol       Date:  2004-10
View more
  34 in total

1.  Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer.

Authors:  Antonio C Westphalen; Galen D Reed; Phillip P Vinh; Christopher Sotto; Daniel B Vigneron; John Kurhanewicz
Journal:  J Magn Reson Imaging       Date:  2012-04-25       Impact factor: 4.813

2.  Pilot Study of the Use of Hybrid Multidimensional T2-Weighted Imaging-DWI for the Diagnosis of Prostate Cancer and Evaluation of Gleason Score.

Authors:  Meredith Sadinski; Gregory Karczmar; Yahui Peng; Shiyang Wang; Yulei Jiang; Milica Medved; Ambereen Yousuf; Tatjana Antic; Aytekin Oto
Journal:  AJR Am J Roentgenol       Date:  2016-06-28       Impact factor: 3.959

3.  Prostate cancer: Post-treatment imaging-a desperate need for solid evidence.

Authors:  Olivier Rouvière
Journal:  Nat Rev Urol       Date:  2015-04-28       Impact factor: 14.432

4.  Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images.

Authors:  M Abd-Alazeez; N Ramachandran; N Dikaios; H U Ahmed; M Emberton; A Kirkham; M Arya; S Taylor; S Halligan; S Punwani
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-03       Impact factor: 5.554

Review 5.  The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer.

Authors:  Henk van der Poel; Nikos Grivas; Pim van Leeuwen; Stijn Heijmink; Ivo Schoots
Journal:  World J Urol       Date:  2019-02-20       Impact factor: 4.226

Review 6.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

Review 7.  The emerging role of diffusion-weighted MRI in prostate cancer management.

Authors:  Edward M Lawrence; Vincent J Gnanapragasam; Andrew N Priest; Evis Sala
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

Review 8.  Multimodality Imaging of Prostate Cancer.

Authors:  Soleen Ghafoor; Irene A Burger; Alberto H Vargas
Journal:  J Nucl Med       Date:  2019-09-03       Impact factor: 10.057

Review 9.  Clinical applications for diffusion magnetic resonance imaging in radiotherapy.

Authors:  Christina Tsien; Yue Cao; Thomas Chenevert
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

10.  Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?

Authors:  Olivio F Donati; Sung Il Jung; Hebert Alberto Vargas; David H Gultekin; Junting Zheng; Chaya S Moskowitz; Hedvig Hricak; Michael J Zelefsky; Oguz Akin
Journal:  Radiology       Date:  2013-03-12       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.